Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 8 clinical trials
Azole-echinocandin Combination Therapy for Invasive Aspergillosis

The goals of this study are 3-fold: First, the main study and the primary endpoint will evaluate if the overall mortality can be decreased with initial azole-echinocandin combination therapy compared with triazole monotherapy in patients with IA and documented voriconazole susceptibility. Second, the study design described will also allow to …

  • 7 views
  • 16 Oct, 2021
  • 4 locations
Study to Optimize the Use of New Antibiotics (NEW_SAFE)

patients who have received either empirical or targeted treatment with ceftaroline, tedizolid, dalbavancin, ceftazidime-avibactam, ceftolozane-tazobactam and isavuconazole from January 2016 to December

antibiotics
antimicrobials
dalbavancin
isavuconazole
vancomycin
  • 3 views
  • 16 Feb, 2022
  • 13 locations
A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101)

Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of SNDX-5613 in patients with acute leukemia. In Phase 2, patients will be enrolled in 3 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, and tolerability of SNDX-5613.

hematopoietic growth factors
myeloid leukemia
total body irradiation
prednisone
cancer
  • 34 views
  • 04 Oct, 2022
  • 17 locations
A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas

looking to see if acalabrutinib can shrink cancer cells. The participants will be given acalabrutinib and isavuconazole, because isavuconazole helps in preventing fungal infections that may occur

mantle cell lymphoma
corticosteroids
chemotherapy regimen
ibrutinib
neutrophil count
  • 1 views
  • 08 Apr, 2022
  • 2 locations
A Study of Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)

Background Secondary central nervous system lymphoma (sCNSL) is cancer that has spread to the central nervous system. Most drugs used to treat it do not cross the blood-brain barrier. This makes it hard to treat. Researchers hope that a new combination of drugs may be able to help. Objective To …

platelet transfusion
cytarabine
anticoagulants
b-cell lymphoma
serum bilirubin
  • 2 views
  • 23 Oct, 2022
  • 1 location
Central Nervous System Disorders Following Hematopoietic Stem Cell Transplantation

such as isavuconazole) and outcome. In addition, risk factors for CNS disorders after allogeneic and autologous HSCT will be analyzed using a prospectively assessed matched control group. In the future

antifungal
cell transplantation
colony stimulating factor
  • 0 views
  • 20 Jun, 2022
  • 17 locations
European Study of Cerebral Aspergillosis Treated With Isavuconazole

first line treatment of invasive aspergillosis. More recently, isavuconazole appeared to be not less effective than voriconazole in the treatment of filamentous IFI, with a better tolerance profile.

  • 0 views
  • 20 Sep, 2021
  • 1 location
Pharmacokinetics of Isavuconazole in Patients in the Intensive Care Unit (ICONIC)

20 patients admitted to the ICU department and receiving isavuconazole as part of standard care for the treatment of fungal infections will be included in the study. Between day 3 and 7, 8

  • 0 views
  • 07 Oct, 2022
  • 4 locations